Central Nervous System Therapeutics Market Size Worth USD 274.69 Billion by 2034 | CAGR: 8.5%

The central nervous system therapeutics market size is expected to reach USD 274.69 Billion by 2034, according to a new study by Polaris Market Research. The report “Central Nervous System Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease (Neurovascular Disease, CNS Trauma, Mental Health), By Drug Class, By Distribution Channel, and By Region – Market Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Central Nervous System (CNS) therapeutics refers to treatments aimed at managing and alleviating disorders affecting the brain, spinal cord, and nerves, such as depression, epilepsy, Parkinson’s disease, and Alzheimer’s. These therapies include medications, biologics, and emerging digital and precision medicine approaches designed to improve neurological function and quality of life.

An aging population is one of the strongest drivers of the CNS therapeutics market. People become more prone to neurological and mental health conditions like Alzheimer’s, Parkinson’s, and dementia as people age. These age-related disorders are chronic and progressive, requiring long-term medical attention and treatment. The rise in the elderly population globally in region such as North America, Europe, and parts of Asia is putting pressure on healthcare systems to provide better and more efficient CNS care. Older adults are also more likely to seek medical help and adhere to treatment plans, driving consistent demand for CNS drugs and therapies. In response, pharmaceutical companies are focusing their research efforts on neurodegenerative conditions and age-related cognitive decline. Governments are further increasing funding for elderly healthcare programs, including those targeting CNS disorders. The need for effective, accessible, and safe CNS therapeutics rise as the global senior population continues to grow, thereby driving the growth.

Central Nervous System Therapeutics Market Report Highlights

•   North America accounted for 39.0% market share in 2025. The regional market dominance is attributed to advanced healthcare infrastructure and widespread awareness of neurological and mental health conditions.
• Asia Pacific held 10.0% of the global revenue share. Rising healthcare investment and growing awareness of neurological disorders drive the regional market growth.
• The mental health segment held 27.0% market share in 2025. The global rise in psychiatric conditions such as depression and anxiety contributes to the segment’s dominance.
• The pain reliever segment accounted for 28.0% market share in 2025. Pain relievers are widely used to manage chronic and acute neurological pain.
• The hospital pharmacy segment accounted for 37.0% revenue share in 2025. Many CNS treatments are administered or initiated in hospital settings.
• The global key market players are Biogen Inc.; Eli Lilly and Company; Johnson & Johnson; Merck & Co., Inc.; Neuraxpharm; Novartis AG; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; UCB S.A.  

Request a free sample copy or read the full market insights:  central nervous system therapeutics market report

Polaris market research has segmented the central nervous system therapeutics market report based on Disease, drug class, distribution channel, and region:

By Disease (Revenue - USD Billion, 2021–2034)

• Neurovascular Diseases
• CNS Trauma
• Mental Health
• Neurodegenerative Diseases
  • Alzheimer’s Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Huntington’s Disease
  • Amyotrophic Lateral Sclerosis
  • Others
• Infectious Diseases
• CNS Cancer
• Others

By Drug Class (Revenue - USD Billion, 2021–2034)

• Anesthetics
• Anticonvulsants
• Antiemetic
• CNS Stimulants
• Pain Relievers
• Others

By Distribution Channel (Revenue - USD Billion, 2021–2034)

• Hospital Pharmacy
• Retail Pharmacy
• Other

By Regional Outlook (Revenue - USD Billion, 2021–2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of APAC
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of MEA